CRISPR-based Spotlight Therapeutics has shut down, former CEO Mary Haak-Frendscho, Ph.D., confirmed with Fierce Biotech. | ...

After privately vying for a change to Dynavax’s corporate strategy for months, life sciences investment firm Deep Track ...

Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

Cabaletta’s new data slice for its investigational CD19-CAR T cell therapy shows “robust benefit” for patients with lupus and ...

The imaging giant is leasing warehouse space and contracting inventory management through a multi-year deal with the ...

Charles River expanded the Memphis facility in November 2022, adding nine processing suites to its 16 clean rooms at the site ...

Sonya Stokes, M.D., an emergency room physician in the San Francisco Bay Area, braces herself for a daily deluge of patients ...

Recce Pharmaceuticals’ synthetic gel successfully treated a range of skin infections in a phase 2 trial, leading the ...

Remote blood collection device maker YourBio Health is revamping its leadership team with the goal of broadening the reach of ...

Clinical trial organization Flourish Research has made a deal with Diablo Clinical Research, acquiring the California-based facility and its expertise in endocrinology, cardiovascular and metabolic ...

Salt Lake City-based accelerator Altitude Lab is hoping it can entice biotechs impacted by the uncertainty surrounding federal grants.

While the FDA’s diversity guidance for clinical trials has been temporarily restored, the page it is housed on now carries a ...